The case for & against
Bull & Bear analysis
Bearish
Haleon plc (LON: HLN) operates as a global consumer healthcare company, specializing in over-the-counter products such as pain relief, oral health, and vitamins/minerals supplements. The firm has established a solid foothold in diverse markets including North America, LATAM, EMEA, and APAC, positioning itself as a leader within the consumer health space. As a part of the broader wellness trend, Haleon aims to improve consumer health outcomes through innovative product offerings while navigating challenges in various markets.
Bull says
- ↑Q2 2026 revenue $2.5 bn (+3.1% YoY); operating margin up 120 bp to 18.5%.
- ↑Emerging markets organic sales rose 6.3% in Q1 2026, led by India and LATAM.
- ↑£500 m share buybacks and 7.6% dividend hike signal strong capital returns.
- ↑Free cash flow reached $450 m in Q2, funding growth and shareholder payouts.
- ↑New products like Paradontax in China and Centrum upgrades gaining share.
- ↑High earnings and dividend yields underscore attractive valuation profile.
Bear says
- ↓North America organic sales fell ~2% as consumer confidence weakened.
- ↓Rising raw material costs from the Middle East erode gross margins.
- ↓Analyst earnings revisions turned negative, signaling lower profit forecasts.
- ↓High short interest and low liquidity reflect investor skepticism.
- ↓Organic growth guidance of 3–5% for 2026 faces headwinds from competition.
- ↓Private label competition and momentum weakness threaten market share gains.
Investment themes with HLN
United Kingdom↑ +0.36%
Stable developed market with finance and pharmaceuticals
EWU · RIO · GSK
International Value↑ +0.55%
Value-oriented stocks outside domestic markets
MRK · SHEL · SAP
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-13-2026neutral
Transcript signals
Bull points
- We did exit last year for the full year growing share on Advil. It was one of the things that contributed to the 71%, and that was a bit of strength as we exited the year
- we feel good about our brand and we feel good about the plans we have in the back half
- It will launch in e-commerce in the back half, and it will full launch in 2026, giving us some reason to believe that we'll have something that's differentiated in the market that can help us there
Bear points
- we did see significant decline. The impact, so it has a 60 basis points impact on the total group in terms of, you know, that would take us to 3.6%. And for North America, it would take North America from minus 1.8 to minus 0.2%. So it is a big change in the quarter, and it has a disproportionate impact
- without that, you'd be in a round of four, I guess, to the guidance point, going down to three and a half
- it will be a drag on the growth in a full year. And it's made it more challenging for us to hit that low end of the guidance
Read full transcript analysis ›